PT  - JOURNAL ARTICLE
AU  - Irina Ruxandra Strambu
AU  - Liesbeth Fagard
AU  - Paul Ford
AU  - Tom Van Der Aa
AU  - Angela De Haas-Amatsaleh
AU  - Eva Santermans
AU  - Christian Seemayer
TI  - Idiopathic pulmonary fibrosis (IPF): observations from a Phase 2 trial of GLPG1205 (PINTA)
AID  - 10.1183/13993003.congress-2020.784
DP  - 2020 Sep 07
TA  - European Respiratory Journal
PG  - 784
VI  - 56
IP  - suppl 64
4099  - http://erj.ersjournals.com/content/56/suppl_64/784.short
4100  - http://erj.ersjournals.com/content/56/suppl_64/784.full
SO  - Eur Respir J2020 Sep 07; 56
AB  - Introduction: Differential diagnosis of IPF is complex and may impact trial recruitment. In the EMPIRE registry (n=3,315; 11 largely Central/Eastern European countries) ~70% of IPF patients had definite usual interstitial pneumonia (UIP).1 PINTA (NCT03725852) is an ongoing randomized Phase 2 trial of GLPG1205 (GPR84 antagonist) on top of standard of care (nintedanib/pirfenidone/neither) in 69 IPF patients recruited in Central/Eastern Europe and Oman.Aim: To evaluate regional differences in recruitment and screen failures in PINTA.Methods: In PINTA, eligible patients (≥40 years old) had an IPF diagnosis within 5 years of screening, confirmed by central review of chest high-resolution computed tomography images and lung biopsy, if available.Results: Of 165 patients screened, 69 (42%) were randomized. Overall screen failure rate was 58%, varying between countries (Fig). Non-confirmation of UIP pattern by central reading accounted for approximately 2/3 of screen failures.Conclusions: PINTA suggests IPF trial recruitment is feasible in Central/Eastern Europe and Oman; non-confirmation of IPF diagnosis by central reading is an important finding.Reference: 1. Summary report, 17 Dec 2019. http://empire.registry.czAcknowledgments: PINTA is sponsored by Galapagos NV (Mechelen, Belgium). Writing support from Hannah Mace, CMPP (Aspire Scientific Ltd, Bollington, UK); funded by Galapagos NV.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 784.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).